真实世界ESME队列中转移性乳腺癌总生存的时间趋势
基于法国ESME-MBC多中心观察性队列16,702例新诊断转移性乳腺癌患者,评估诊断年份对总生存的独立影响。
要点
- HR+/HER2-和HR-/HER2-亚组诊断年份与OS无显著关联。
核心结论
- 转移性乳腺癌患者的总生存在过去十年略有改善,但改善仅限于HER2+病例,其他亚型需新策略。
研究设计与样本
- ESME-MBC(NCT03275311)为法国国家多中心观察性队列,纳入2008年1月1日至2014年12月31日新诊断的16,702例转移性乳腺癌患者。
- 16,680例符合条件,其中15,085例有完整免疫组化数据,分为HR+/HER2-(N=9907)、HER2+(N=2861)和HR-/HER2-(N=2317)亚组。
- 在全队列及各亚组中进行总生存的多变量分析。
主要发现
- 全队列中位OS为37.22个月(95%CI 36.3-38.04)。
- HR+/HER2-、HER2+和HR-/HER2-亚组的中位OS分别为42.12个月(95%CI 40.90-43.10)、44.91个月(95%CI 42.51-47.90)和14.52个月(95%CI 13.70-15.24)。
临床怎么用
- 真实世界数据提示HER2+转移性乳腺癌患者总生存随诊断年份改善,支持该亚型治疗进展的临床获益。
- HR+/HER2-和HR-/HER2-转移性乳腺癌的总生存未见随时间显著改善,提示需针对这些亚型探索新的治疗策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIM: Real-life analysis of overall survival (OS) trends among metastatic breast cancer (MBC) patients may help define medical needs and evaluate the impact of public health investments. The present study aimed to evaluate the independent impact of the year of MBC diagnosis on OS in the Epidemio-Strategy-Medical-Economical (ESME)-MBC cohort. METHODS: ESME-MBC (NCT03275311) is a French, national, multicentre, observational cohort including 16,702 consecutive newly diagnosed MBC patients (01 January 2008-31 December 2014). Of 16,680 eligible patients, 15,085 had full immunohistochemistry data, allowing classification as hormone receptor-positive and HER2-negative (HR+/HER2-, N = 9907), HER2-positive (HER2+, N = 2861) or triple-negative (HR-/HER2-, N = 2317) subcohorts. Multivariate analyses of OS were conducted among the full ESME cohort and subcohorts. RESULTS: Median OS of the whole cohort was 37.22 months (95% confidence interval [CI], 36.3-38.04). Year of diagnosis was an independent predictor of OS (hazard ratio 0.98 [95% CI, 0.97-1.00], P = .01) together with age, subtype, disease-free interval, visceral metastases and number of organs involved. Median OS of HR+/HER2-, HER2+ and HR-/HER2- subcohorts was, respectively, 42.12 (95% CI, 40.90-43.10), 44.91 (95% CI, 42.51-47.90) and 14.52 (95% CI, 13.70-15.24) months. Year of diagnosis was a strong independent predictor of OS in HER2+ subcohort (hazard ratio 0.91 [95% CI, 0.88-0.94], P < .001), but not in HR+/HER2- nor HR-/HER2- subcohorts (hazard ratio 1.00 [95% CI, 0.98-1.01], P = .80 and 1.00 [95% CI, 0.97-1.02], P = .90, respectively). CONCLUSIONS: The OS of MBC patients has slightly improved over the past decade. However, this effect is confined to HER2+ cases, highlighting the need of new strategies in the other subtypes.
引用
- Gobbini E, Ezzalfani M, Dieras V, et al. Time trends of overall survival among metastatic breast cancer patients in the real-life ESME cohort. Eur J Cancer. 2018. PMID: 29660596. doi:10.1016/j.ejca.2018.03.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。